Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Aug 17, 2026 (2 months ago)

0.9% Sodium Chloride Injection USP 500 mL

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of particulate matter: Particulates identified as fiberglass

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 units per case. Baxter Healthcare Corporation, Deerfield, IL, 60015, USA, Made in USA, NDC 0338-0049-03

Affected NDC 0338-0049-03

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Sodium Chloride
NDC 00338-0049
9 g/1000mL Injection, Solution
Intravenous
Baxter Healthcare Corporation Rx
Recalling firm
Baxter Healthcare Corporation
NDC code
0338-0049-03
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Aug 25, 2026 · FDA notice with lot numbers
FDA recall number
D-0849-2026 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other recalls by Baxter Healthcare Corporation

All 2026 recalls
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026
Class II · Moderate risk

Vasopressin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-9647-12 D-0819-2026

Other particulate / foreign matter recalls from 2026

All particulate / foreign matter recalls
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026